eligible ages (years): 18.0-999.0,  All  Chest Pain Ischemia Patient referred for elective coronary angiography because of a reasonable clinical suspicion of coronary ischemia Presence of angina or an anginal equivalent (including chest, back, shoulder, arm, neck, jaw discomfort, or shortness of breath brought on by physical exertion, emotional stress, or certain times of day/month)  Asymptomatic (such as a pre-op cath) Status-post heart transplant Status-post coronary artery bypass grafting Age <18 Renal insufficiency (creatinine >1.5) Presence of an acute coronary syndrome (STEMI or Tako-tsubo, an abnormal ejection fraction (EF<55%), cardiogenic shock, or recent VT/VF Presence of another likely explanation of chest pain, such as pulmonary hypertension or aortic stenosis History of adverse reaction to any of the medications being used (acetylcholine, nitroglycerin, adenosine, or heparin) Currently taking vasoactive medication (such as nitroglycerin) Inability to provide an informed consent, including an inability to speak, read, or understand English, Spanish, Chinese, Farsi, Japanese, Korean, Russian, or Vietnamese


A 65 yo male with no significant history of cardiovascular disease presents to the emergency room with acute onset of shortness of breath, tachypnea, and left-sided chest pain that worsens with inspiration. Of note, he underwent a right total hip replacement two weeks prior to presentation and  was unable to begin physical therapy and rehabilitation for several days following the surgery due to poor pain management. Relevant physical exam findings include a respiratory rate of 35 and right calf pain.

eligible ages (years): 19.0-999.0,  All  Chest Tube Removal Patients who are post thoracotomy, pulmonary resection (wedge, lobectomy, segmentectomy, pneumonectomy), AND Have at least one chest tube  Less than 19 years old With interstitial lung disease, OR Any patient intubated


eligible ages (years): 0.0-999.0,  All  Dyspnea Heart Failure Asthma COPD patient had to present with shortness of breath as the primary complaint (defined as either the sudden onset of dyspnea without history of chronic dyspnea or an increase in the severity of chronic dyspnea)  age <18 years history of renal insufficiency, trauma, severe coronary ischemia (unless patient's predominant presentation was dyspnea), and other causes of dyspnea pneumonia pulmonary embolism carcinoma pneumothorax pleural effusion intoxications (drugs) anaphylactic reactions upper airway obstruction


eligible ages (years): 18.0-999.0,  All  Venous Thromboembolism Age > 18 years first episode of objectively documented symptomatic idiopathic VTE, either proximal lower extremity deep vein thrombosis (DVT) and/or pulmonary embolism (PE) Unprovoked or idiopathic , or associated with one or more of the following favouring factors minor general surgery, arthroscopy or laparoscopy pregnancy or puerperium hormonal treatment (contraceptive or replacement therapy) travel minor traumas hospitalization in a medical ward reduced mobility (non complete immobilization) at least six months of VKA therapy ( or other type) for at least 3 months and not longer than 12 months ability to provide informed consent  Two or more episodes of objectively documented proximal DVT and or PE ( previous distal of superficial vein thrombosis are not Index event was isolate distal ( calf) vein thrombosis Index event was PE associated with shock or prolonged hypotension at high risk Index event was DVT in sites different from the lower limbs Pregnancy or puerperium ( first 6 weeks after delivery) at the time of the visit Solid or haematological malignancy in the active phase or undergoing chemotherapy or radiotherapy Antiphospholipid antibody syndrome, diagnosed according to the Sydney Hereditary antithrombin deficiency Necessity to prolong anticoagulation for any reason (due to the thrombotic event or other clinical indications Severe respiratory or heart failure (NYHA classes: III or IV)


eligible ages (years): 21.0-80.0,  All  Arthroplasty, Replacement, Knee The subject is a male or non-pregnant female 21-80 years of age at the time of enrollment The subject requires a primary cemented total knee replacement The subject has a diagnosis of osteoarthritis (OA), traumatic arthritis (TA), or avascular necrosis (AVN) The subject has intact collateral ligaments The subject has signed the IRB approved, study specific Informed Patient Consent Form The subject is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation  The subject has inflammatory arthritis The subject is morbidly obese, BMI > 40 The subject has a history of total or unicompartmental reconstruction of the affected joint The subject has had a high tibial osteotomy or femoral osteotomy The subject has a neuromuscular or neurosensory deficiency that would limit the ability to assess the performance of the device The subject has a systemic or metabolic disorder leading to progressive bone deterioration The subject is immunologically suppressed, or receiving chronic steroids (>30 days duration) The subject's bone stock is compromised by disease or infection and cannot provide adequate support and/or fixation to the prosthesis The subject has had a knee fusion at the affected joint The subject has an active or suspected latent infection in or about the knee joint


eligible ages (years): 18.0-999.0,  All  Idiopathic Venous Thromboembolism First episode of major unprovoked VTE VTE objectively proven VTE treated for 5-12 months with anticoagulant therapy authorized for the II study (initial or ongoing therapy) Absence of recurrent VTE during the treatment period  Less than 18 years of age Patients who have already discontinued anticoagulant therapy Patients requiring ongoing anticoagulation for reasons other than VTE Being treated for a recurrent unprovoked VTE Patients with high risk thrombophilia patients who plan on using exogenous estrogen(OCP,HRT)if anticoagulant therapy is discontinued Patients with pregnancy associated VTE Geographically inaccessible for follow-up Patients unable or unwilling to provide informed consent


eligible ages (years): 18.0-999.0,  All  Acute Pulmonary Embolism acute (symptoms <24 hrs) with right ventricular dilatation (>30 mm end diastolic, systolic PAP > 50 mmHg absence of right ventricular wall hypertrophy)  age below 18 years or above 70 years body mass index >35 kg/m2 duration of symptoms >24 hours (since onset or acute increase in symptoms) severe circulatory shock (systemic blood pressure systolic <80 mmHg, or diastolic blood pressure <45 mmHg) or respiratory failure, requiring mechanical ventilation patients who, in the opinion of the supervising physician, require thrombolytic therapy severe pre-existent cardiopulmonary disease (heart failure, obstructive pulmonary disease, emphysema) atrial fibrillation refusal or inability to give informed consent


eligible ages (years): 40.0-75.0,  All  Acute Coronary Syndrome Myocardial Infarction Unstable Angina Pectoris Participant had at least five minutes of chest pain or equivalent (chest tightness; pain radiating to left, right, or both arms or shoulders, back, neck, epigastrium, jaw/throat; or unexplained shortness of breath, syncope/presyncope, generalized weakness, nausea, or vomiting thought to be of cardiac origin) at rest or during exercise within 24 hours of ED presentation, warranting further risk stratification, as determined by an ED attending 2 or more cardiac risk factors (diabetes, hypertension, hyperlipidemia, current smoker and family history of coronary artery disease) Able to provide a written informed consent <75 years of age, but >40 years of age Able to hold breath for at least 10 seconds Sinus rhythm  New diagnostic ischemic ECG changes (ST-segment elevation or depression > 1 mm or T-wave inversion > 4 mm) in more than two anatomically adjacent leads or left bundle branch block Documented or self-reported history of CAD (MI, percutaneous coronary interventions [PCIs], coronary artery bypass graft [CABG], known significant coronary stenosis [>50%]) Greater than 6 hours since presentation to ED BMI >40 kg/m2 Impaired renal function as defined by serum creatinine >1.5 mg/dL* Elevated troponin-T (> 0.09 ng/ml) Hemodynamically or clinically unstable condition (BP systolic < 80 mm Hg, atrial or ventricular arrhythmias, persistent chest pain despite adequate therapy) Known allergy to iodinated contrast agent Currently symptomatic asthma Documented or self-reported cocaine use within the past 48 hours (acute)


eligible ages (years): 14.0-999.0,  All  Lower Abdominal Pain Right Iliac Fossa Pain Acute Appendicitis Age >14 years Lower / RIF Abdominal Pain Clinical Suspicion of Acute Appendicitis i.e Alvarado Score 5-6 (equivocal for acute appendicitis) Alvarado Score 7-8 (probably appendicitis) Alvarado Score 9-10 (highly likely appendicitis) Informed consent (patient or legal representative)  Diffuse peritonitis Antibiotic (Penicillin) documented allergy Ongoing previously started antibiotic therapy Previous appendectomy Positive pregnancy test IBD history or suspicion of IBD recrudescence


eligible ages (years): 18.0-999.0,  All  Pulmonary Embolism Must be Age greater than or equal to 18 Obtain informed written consent Diagnosed with acute pulmonary embolism (PE) (< 14 days) Catheter-directed therapy (CDT) was performed to treat acute PE


eligible ages (years): 0.0-999.0,  All  Femoral Neck Fracture femoral neck fracture partial hip replacement  r/o infection reoperation mental change


eligible ages (years): 18.0-65.0,  All  Postoperative Pain laminectomy  r/o infection reoperation mental change allergy to local anesthetics


eligible ages (years): 18.0-999.0,  All  Medical Prevention Therapy Objectively confirmed VTE Initiation of enoxaparin treatment within Day 0-10 after diagnosis of VTE Outpatients who will be treated with enoxaparin + VKA in combination are permitted to receive initial treatment other than enoxaparin for a maximum of 48 hours or 2 treatment doses preceding entry into the study Outpatients on enoxaparin monotherapy are permitted to receive up to 10 days of treatment other than enoxaparin preceding entry into the study  Medical or psychiatric disorders associated with altered cognition or mentation that precludes understanding of the informed consent process


eligible ages (years): 18.0-999.0,  All  Nonalcoholic Fatty Liver Disease Coronary Artery Disease Patients at intermediate risk for significant CAD was admitted to the hospital with the diagnosis of chest pain or undergoing elective CT coronarography due to suspection of coronary artery disease Male and female 18years or older Able to provide written informed consent Intermediate Risk patients for having significant CAD is deﬁned as chest pain or dyspnea in the presence of negative stress tests the absence of chest pain but positive stress tests the absence of chest pain and of positive stress tests but intermittent arrhythmias  Acute coronary syndrome presentation ST segment deviation on ECG and/or Cardiac troponin elevation Chest pain in combination with positive tests for myocardial ischemia Hemodynamic instability on presentation Inability to write inform consent Age <18 years Participation in an investigational study within the previous 30days


eligible ages (years): 18.0-999.0,  All  Venous Thromboembolism Neoplasms Patients with cancer and confirmed pulmonary embolism (PE) or deep vein thrombosis (DVT) of the leg who have been treated for minimally 6 and maximally 12 months with therapeutic doses of anticoagulants, i.e. LMWH or VKA or a new anticoagulant in a trial Written informed consent Indication for long-term anticoagulant therapy (e.g. because of metastasized disease, chemotherapy)  Legal age limitations (country specific), minimum age at least 18 years Indications for anticoagulant therapy other than DVT or PE Any contraindication listed in the local labeling of LMWH or VKA Childbearing potential without proper contraceptive measures, pregnancy or breastfeeding Life expectancy <3 months


eligible ages (years): 18.0-999.0,  All  Knee Arthroscopy Analgesia those undergoing knee arthroscopy for: diagnostic purposes, removal of loose bodies, articular cartilage debridement or, meniscectomy age over 18 years  American Society of Anaesthesiologists (ASA) grade ≥3 arthroscopic assisted osteotomies a history of two or more prior procedures on the ipsilateral knee post-operative morbidities indirectly linked to the procedure (e.g. anaesthetic complications, DVT or PE) systemic steroid requirements previous intra-articular anaesthetic or steroid injection within the last three months intra-articular HA injection within the last nine months intra-articular sepsis within the previous three months prior history of knee arthroplasty, peri-articular fracture, ligamentous instability, inflammatory arthritis or a previous diagnosis of Complex Regional Pain Syndrome


eligible ages (years): 18.0-999.0,  All  Osteoarthritis, Hip Total hip replacement for osteoarthrosis Living within 30 km from the hospital Motivated to attend training 2 times/week in 10 weeks Reduced functional ability measured as: HOOS score < 67 written informed consent  Comorbidities such as cancer, neuromuscular diseases, heart diseases etc Cognitive impairment Body mass index > 35 Resurfacing prosthesis Scheduled additional prosthetic surgery in lower extremity within 6 months


eligible ages (years): 18.0-65.0,  All  Fracture Fixation Intra-Articular Fractures Acetabulum Acetabular fracture deemed to require open reduction and internal fixation by one of the three principle attending surgeons Fixation must require a single non-extensile posterior approach (Kocher-Langenbeck) Posterior wall, Posterior column, certain simple transverse and transverse associated with a posterior wall, T-type, and posterior wall-posterior column fracture types Ages 18-65 Patient or family must consent to the research protocol  Not meeting the aforementioned Unstable hemoglobin levels for three days prior to acetabular surgery (i.e. no other bleeding sources) Revision surgery Surgery occurring more than two weeks post-injury History of blood dyscrasias or immunocompromised patients Patients with medical conditions requiring anticoagulation or INR above 1.5 Obese patients (BMI >35) Known ongoing infection (local or systemic) Pregnant women


eligible ages (years): 0.0-0.077,  All  Newborn Pain Respiratory Therapy Techniques Newborns up to 28 days with any weight and gestational age in ventilatory support or oxygen therapy and clinical indication for Physical Therapy  Newborns with contraindication of respiratory therapy, those that had problems during any of the study procedures and changes in those suffering from respiratory support or oxygen therapy during data collection If there was failure to collect any of the parameters for evaluating the newborn also was no longer part of the sample


eligible ages (years): 0.083-2.0,  All  Acute Respiratory Failure PaO2/FiO2 ratio <300 Respiratory rate >50 breaths/min Chest x-ray compatible with pulmonary infection No clinical improvement after breathing oxygen at 8 l/min or more for at least 15 min  Presence of an endotracheal tube or a tracheostomy before PICU admission Facial deformities Upper airway obstruction Cyanotic congenital heart disease Facial trauma Recurrent apnea Neuromuscular weakness Pulmonary hypoplasia Pulmonary vascular anomalies Imminent respiratory or cardiac arrest


eligible ages (years): 60.0-85.0,  All  Knee Osteoarthritis Osteoarthritis (OA) of the knee for >6 months moderate to severe pain immediately following a 50-foot walk knee pain primarily due to tibiofemoral OA and not from patellofemoral OA bilateral standing anterior-posterior radiograph demonstrating grade 2 or 3 OA of the target knee willing and able to participate in regular exercise for four months free from musculoskeletal limitations that would preclude resistance exercise participation free of abnormal cardiovascular responses during the screening graded maximal walk test  unable to walk regular resistance exercise training (>3X week) within the past 6 months specific low back pain or acute back injury spinal stenosis that precludes walking one block due to neurogenic claudication any major injury to either knee within the prior 12 months any surgery to either knee within the last 12 months lumbar radiculopathy vascular claudication significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or chondromalacia in either knee have had corticosteroid or viscosupplement injections within three months of study participation


eligible ages (years): 18.0-999.0,  All  Venous Thromboembolism Postpartum Women must be at high risk for thromboembolism for one of the following reasons Known low risk thrombophilia (Known = diagnosed prior to enrollment and low risk thrombophilia includes heterozygous factor V Leiden or prothrombin gene variant or protein C deficiency or protein S deficiency. If not previously tested then assumed not to have thrombophilia) Immobilization (defined as >90% of waking hours in bed, of a week or more at any point in the antepartum period) OR any two of the following reasons Postpartum infection (fever (temperature>38.5oC) and clinical signs/symptoms of infection and elevated neutrophil count (higher than local lab normal)) Postpartum hemorrhage (Estimated blood loss >1000 ml during delivery and postpartum) Pre-pregnancy BMI >25 kg/m2 Emergency cesarean birth (emergency = not planned prior to onset of labour) Smoking >5 cigarettes per day prior to pregnancy Preeclampsia (blood pressure ≥ 140mmHG systolic and/or ≥90 mmHg diastolic on at least one occasion and proteinuria (1+ on urine dipstick or 300mg/dl or total excretion of 300mg/24 hours) or typical end-organ dysfunction  Less than 6 hours or more than 36 hours since delivery at the time of randomization Need for anticoagulation as judged by the local investigator, may but not limited to Personal history of previous provoked or unprovoked VTE (DVT or PE) Continuation of LMWH that was started in the antenatal period for VTE prophylaxis Mechanical heart valve Known high-risk thrombophilia (Known = diagnosed prior to enrolment and high-risk thrombophilia includes deficiency of antithrombin (at least 1 abnormal lab result), persistently positive anticardiolipin antibodies (> 30U/ml on two measurements a minimum of six weeks apart), persistently positive Anti B2 glycoprotein antibodies (> 20U/ml on two measurements a minimum of six weeks apart), persistently positive lupus anticoagulant (positive on two measurements a minimum of six weeks apart), homozygous factor V Leiden (FVL), homozygous prothrombin gene mutation (PGM), compound heterozygosity factor V Leiden (FVL) and prothrombin gene mutations (PGM), more than 1 thrombophilia (any combination of 2 or more: FVL, PGM, protein C deficiency, protein S deficiency). If not previously tested then assumed not to have thrombophilia) Contraindication to heparin therapy, including History of heparin induced thrombocytopenia (HIT) Platelet count of less than 80,000 x 106/L on postpartum Complete Blood Count(CBC) Hemoglobin ≤ 75 g/L on postpartum CBC


eligible ages (years): 18.0-999.0,  All  Thoracotomy Chronic Pain Age > 18 Able to cooperate able to speak and read Danish  repeat surgery cognitive dysfunction other nerve injury on the thorax abuse (medicine/ alcohol etc)


eligible ages (years): 40.0-75.0,  All  Lung Cancer Pulmonary Complications medical diagnosis of lung cancer and an indication for lung resection (lobectomy, bilobectomy and pneumonectomy) with posterolateral thoracotomy aged between 40 and 75 years  Patients who refused to participate in the survey lung resection with incisions other than posterolateral patients who had contraindications to the use of noninvasive ventilation


eligible ages (years): 18.0-65.0,  All  Postoperative Pain Tonsillectomy  mental change allergy to local anesthetics


eligible ages (years): 18.0-999.0,  All  Axial Spondyloarthritis Male and female subjects aged 18 years and over at the time of consent to the study Diagnosis of SpA, as defined by the ASAS for axial SpA Axial involvement refractory to previous or current intake of NSAIDs, defined as at least 2 NSAIDs at maximum tolerated dose determined from past medical history taken for a duration of > 1 month (for both NSAIDs combined) before the Screening visit Active axial involvement defined by mini  Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial Subjects who have received any previous treatment with etanercept or other TNFα inhibitors or biologic agents Subjects with a known or expected allergy, contraindication, or hypersensitivity to etanercept or its excipients


eligible ages (years): 17.0-999.0,  All  Venous Thromboembolism Delivery of Health Care Quality Improvement Inpatients with age > 17 years old  Outpatients Inpatients with age less than or equal to 17 years old


eligible ages (years): 15.0-999.0,  All  Pain Pain, Postoperative Funnel Chest Patients undergoing minimally invasive repair of pectus excavatum Age > 15 years old  Previous thoracic surgery interventions Disorders affecting the central or peripheral nervous system Chronic pain (pain intensity assessed by numerical rating scale > 3) Inability to speak and understand Danish (instructions, questionnaires) Inability to understand and participate in experimental pain modulation Psychiatric disorders (ICD-10) A history of frostbite in the non-dominant upper limb Sores or cuts on non-dominant upper limb Cardiovascular disease A history of fainting and/or seizures


eligible ages (years): 18.0-999.0,  All  Total Hip Arthroplasty Patients scheduled for unilateral total hip replacement Consent to spinal anaesthesia ASA Grade I to III  Patient refusal Mini-Mental Score < 25 Allergy to bupivacaine, morphine, paracetamol, diclofenac Skin lesions/infection at site of injection Uncorrected renal dysfunction Coagulation disorders chronic pain condition other than hip pain


eligible ages (years): 18.0-999.0,  All  Ovarian Carcinoma Fallopian Tube Cancer Primary Peritoneal Cancer Subjects who have received at least one vaccine under protocol UPCC-19809 or UPCC-29810 ECOG performance status 0 or 1 Subject has sufficient vaccine (2 vaccine doses are sufficient) Must be at least 4 weeks post-operative Blood coagulation parameters: PT such that international normalized ratio (INR) is less than1.5 (or an in-range INR, usually between 2 and 3, if a subject is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thromboembolus) and a PTT less than1.2 times the upper limit of normal Subject must be 18 years of age or older Life expectancy of greater than 4 months Normal organ and bone marrow function as defined by: Absolute neutrophil count greater than 1,000/microliter, Platelets greater than 100,000/microliter, Hematocrit greater than 30%, AST (SGOT)/ALT(SGPT) less than 2.5 X institutional upper limit of normal, Bilirubin less than 2.0 mg/dL unless secondary to bile duct blockage by tumor, and Creatinine less than 1.8 mg/dL  Subjects who require or are likely to require more than a two-week course of corticosteroids for intercurrent illness. Subjects must complete therapy prior to enrollment. Topical corticosteroids should be stopped at least 2 weeks prior to enrollment and systemic corticosteroids should be stopped at least 4 weeks prior to enrollment Subjects with any acute infection that requires specific therapy. Acute therapy must have been completed at least seven days prior to study enrollment Subjects with any underlying conditions, which would contraindicate therapy with, study treatment (or allergies to reagents used in this study) Subjects with prior history or symptoms suggestive of partial or complete bowel obstruction Subjects receiving class III antiarrythmic medications Subjects receiving medications that might affect immune function. Additionally, H2 blockers are excluded, as are all antihistamines five days before and five days after each injection of study drug. NOTE: The following are exceptions: Proton pump Inhibitors (PPIs), including COX-2 inhibitors, acetaminophen Subjects who are allergic to Aspirin are excluded Development of clinically significant co morbid disease that would contraindicate study therapy or confuse interpretation of study results Subjects with a History of bowel obstruction, including sub-occlusive disease, related to the underlying disease and history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess Subjects with evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction


eligible ages (years): 40.0-80.0,  All  Pulmonary Disease, Chronic Obstructive Type of subject: outpatient Informed consent: Subjects must give their signed and dated written informed consent to participate Gender: Male or female. Female subjects must be post-menopausal or using a highly effective method for avoidance of pregnancy. The decision to or women of childbearing potential may be made at the discretion of the investigator in accordance with local practice in relation to adequate contraception Age: >=40 and <=80 years of age at Screening (Visit 1) Tobacco use: Subjects with a current or prior history of >=10 pack-years of cigarette smoking at screening (Visit 1). Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1 Airflow Obstruction Subjects with a measured post-albuterol/salbutamol forced expiratory volume in 1 second (FEV1)/(forced vital capacity)FVC ratio of <=0.70 at Screening (Visit 1) Subjects with a measured post-albuterol/salbutamol FEV1 >=50 and <=70% of predicted normal values calculated using III reference equations [Hankinson, 1999; Hankinson, 2010] at Screening (Visit 1) Post-bronchodilator spirometry will be performed approximately 15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via a metered dose inhaler (MDI )with a valved-holding chamber. The FEV1/FVC ratio and FEV1 percent predicted values will be calculated Symptoms of COPD: Subjects must score 2 or higher on the modified Medical Research Council Dyspnea scale (Visit 1)  Pregnancy: Women who are pregnant or lactating Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they also have a current diagnosis of COPD) alpha 1-antitrypsin deficiency: Subjects with known alpha-1 antitrypsin deficiency as the underlying cause of COPD Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases Lung resection or transplantation: Subjects with lung volume reduction surgery within the 12 months prior to Screening or having had a lung transplant A moderate/severe COPD exacerbation that has not resolved at least 14 days prior to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if applicable) Current severe heart failure (New York Heart Association class IV). Subjects will also be excluded if they have a known ejection fraction of <30% or if they have an implantable cardioverter defibrillator (ICD) Other diseases/abnormalities: Any life-threatening condition with life expectancy <3 years, other than vascular disease or COPD, that might prevent the subject from completing the study End stage chronic renal disease: Subjects will be excluded if on renal replacement therapy (hemodialysis or peritoneal) Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g. beta-agonists, corticosteroid) or components of the inhalation powder (e.g. lactose, magnesium stearate). In addition, patients with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates the subject's participation will also be excluded


eligible ages (years): 18.0-85.0,  All  Postoperative Pain level posterior lumbar fusion  mental change allergy to local anesthetics chronic analgesics user


eligible ages (years): 18.0-999.0,  All  Pulmonary Embolism patients with acute pulmonary embolism diagnosed in the emergency departement  patient under guardianship patient without social insurance pregnant women refusal to sign the consent myocardial infarction in the 10 days before pulmonary embolism


eligible ages (years): 18.0-999.0,  All  Malignant Pleural Mesothelioma Subjects must have histologically confirmed MPM (epithelial or biphasic) Subjects must have completed standard first line therapy with a platinum-based double regimen and had PD or they must have chosen not to pursue primary standard of care therapy ECOG performance status 0 to 1 Age greater than 18 years Life expectancy > 4 months At least 2 weeks since prior and no other concurrent chemotherapy, radiotherapy, or immunotherapy (e.g., interferons, tumor necrosis factor, interleukins, or monoclonal antibodies). In addition, the patient must have fully recovered from any adverse events related to these agents More than 4 weeks since prior and no other concurrent investigational agents Subjects must have measurable disease as defined by accepted MPM measurement techniques (modified criteria) Blood coagulation parameters: PT such that international normalized ratio (INR) is < 1.5 (or an in-range INR, usually between 2 and 3, if a subject is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thromboembolus) and a PTT < 1.2 times the upper limit of normal Subjects must have adequate venous peripheral access for apheresis. Patients must also have adequate venous access for subsequent modified CIR T-cell administration which can be done through a central venous access (e.g. port of systemic chemotherapy)  Previously treated with any investigation therapy within 1 month prior to screening Sacromatoid MPM histology which does not express mesothelin Prior invasive malignancies unless surgically and medically cured without evidence of recurrent disease for 5 years with the exception of non-melanoma skin cancer, prostate cancer with PSA level < 1.0 Prior hematologic malignancy with bone marrow transplantation or immune modifying therapy within the past 4 weeks with the exception of thyroid replacement Use of immunosuppressive drugs with 4 weeks prior to study entry, or anticipated use of immunosuppressive agents Any clinically -significant pericardial effusion, CHF (NY Heart Association Grade II-IV ), or cardiovascular condition Any clinically -significant pleural effusion or ascites that cannot be drained with standard approaches or with pre-enrollment in dwelling drainage device placement Forced vital capacity < 50% predicted, DLCO < 40% predicted Underlying lung disease requiring supplemental oxygen therapy Have a recognized immunodeficiency disease including cellular immunodeficiency, hypogammaglobulinemia, or dysgammaglobulinemia; patients who have acquired hereditary, congenital immunodeficiency


eligible ages (years): 18.0-99.0,  All  Urinary Incontinence includes English-speaking women over the age of 18 who have been admitted to the Rehabilitation Institute of Chicago with reports of urinary incontinence in the past 3 months. Those who report "yes" to the screening questions who fit the above will be screened by the principal investigator to ensure they fall into the criteria  Non-English speaking women under the age of 18, or those that do not give consent to participate in the study will not be enrolled. Also excluded will be any woman who has any chance of being pregnant or having an active urinary tract infection. No women with active infection lesions, unknown vaginal bleeding or those who have never had any kind of pelvic examination will be included in the study. Other women with a neurogenic bladder or admission FIM scores on sections Comprehension and Memory of below 4. Women with reports of significant pelvic pain or recent pelvic surgery or radiation or post-partum in last 6 months will be excluded


eligible ages (years): 18.0-75.0,  All  Pulmonary Thromboembolisms Pulmonary Embolism 18 y≤Age≤75y Acute PE (first symptoms occurred 14 d or less before randomization) confirmed by lung scan, or a positive computed tomographic pulmonary angiogram, or a positive selective pulmonary angiogram Hemodynamic stability, diastolic pressure>90mmHg RV dysfunction confirmed by echocardiography (≥1 criterion), except left-side heart disease, congenital heart disease and mitral valve disease Increase of the right ventricle showed presented with RV end-diastolic anteroposterior diameter >25 mm, Right/left ventricular end-diastolic diameter >1 (apical or subcostal 4-chamber view) or Right/left ventricular end-diastolic anteroposterior diameter >0.5 Hypokinesis of RV-free wall (range of motion less than 5 mm) Tricuspid regurgitation pressure >30mmHg  RV anterior wall thickness > 5mm confirmed by echocardiography Active internal bleeding and spontaneous intracranial hemorrhage in preceding 6 months Major surgery, organ biopsy or non-compressible punctures within 2 weeks Ischemic stroke occurred within 2 months Gastrointestinal bleeding within 10 days Severe trauma occurred within15 days Neurosurgery or eye surgery within 1 months Severe hypertension difficult to control (systolic blood pressure>180mmHg or diastolic blood pressure>110mmHg) Cardiopulmonary resuscitation Platelet count less than 100×109 / L


eligible ages (years): 19.0-999.0,  All  Air Embolism as A Complication of Medical Care Subject is undergoing ERCP as part of their medical care Subject will be of age 19 or older  Subject positioning for the ERCP is prone, thereby inhibiting the performance of the TTE Subject intolerance of the pressure of the TTE probe Subject body habitus interferes with obtaining adequate images to assess for intra-cardiac air


eligible ages (years): 18.0-70.0,  All  Degenerative Joint Disease of Hip and Knee. Undergoing a hip arthroplasty, total knee arthroplasty, hip fracture repair American Society of Anesthesiologist rating I-III as determined by your anesthesiologist  Pregnancy and breast feeding An allergy to any of the drugs to be used in the study (midazolam, Celecoxib, gabapentin, hydromorphone, bupivacaine) History of a sleep disorder (Obstructive sleep apnea or daytime somnolence) History of taking chronic narcotic pain medications or gabapentin History of rheumatoid arthritis, a psychiatric disorder, or diabetes with impaired renal function History of alcohol or illicit drug abuse History of a kidney or liver problem Inability or unwilling to use patient-controlled analgesia Unable to meet the for removal of the endotracheal tube in the Operating Room History of asthma, hives or an allergic type reaction following an aspirin or other drug such as Ibuprofen


eligible ages (years): 18.0-999.0,  All  Traumatic Rib Fracture A subject must meet the following to take part in the study Subjects 18 years of age and greater Inpatient on the BWH SICU, MICU, or hospital floor ward Non-intubated at the time of block placement Traumatic Rib Fractures three or greater Block able to be placed within 12-24 hours of presentation to the emergency room Ability to provide written informed consent Compliance with all ASRA and BWH Regional Anesthesia in Anticoagulated Patient guidelines for coagulation status  Subject is pregnant Subject not expected to survive 48 hours due to traumatic injuries Allergy to Ropivacaine or other local anesthetic Any significant concomitant injuries potentially confounding data acquisition (e.g., traumatic brain injury, long bone fractures, intra-abdominal injuries) Known allergy to lidocaine Inability to provide written, informed consent Known opioid medication dependence Non-compliance with ARSA and BWH Regional Anesthesia in Anticoagulated Patient Guidelines


eligible ages (years): 18.0-999.0,  All  Acute Pulmonary Embolism consecutive patients with acute pulmonary embolism  age <18 years


eligible ages (years): 18.0-65.0,  All  Postoperative Pain Total thyroidectomy  mental change allergy to local anesthetics


eligible ages (years): 18.0-65.0,  All  Postoperative Pain Laparoscopic cholecystectomy  mental change allergy to local anesthetics


eligible ages (years): 0.0-999.0,  All  Pulmonary Embolism Pulmonary Embolism Without Mention of Acute Cor Pulmonale all patients referred to the ICU with suspected APE


eligible ages (years): 18.0-999.0,  All  Pulmonary Embolism Patients with clinical suspected pulmonary embolism Simplified Well's score>4 (PE likely) or D-dimer value ≥500ng/ml Patients that undergo MCTPA in the Emergency Department for suspected pulmonary embolism  Refused consent Less than 18 years old Not possible to perform ultrasound scan within 3 hours before MCTPA


eligible ages (years): 40.0-80.0,  All  Coronary Disease non-acute chest pain those who underwent CT calcium scoring availability of all relevant risk factor information  previous coronary disease i.e., myocardial infarction or revascularization


eligible ages (years): 18.0-999.0,  All  Atrial Fibrillation patients with atrial fibrillation foreseen for Pradaxa anticoagulation according to physician's decision for stroke prevention patients with mild or moderate renal impairment age >= 18 years at enrollment  severe renal impairment (Creatinine Clearance < 30 ml/min)


eligible ages (years): 16.0-999.0,  All  Chest Pain All patients over the age of 18 years presenting with the leading symptom of first time or recurrent acute chest pain in the emergency room of the Department of Internal Medicine, University Hospital of Zurich  Missing informed consent Cardiopulmonary unstable patients No self reported chest pain Recent thoracic surgery within1 year, inflammatory joint disease, fibromyalgia, cardiogenic shock


eligible ages (years): 18.0-999.0,  All  Hyperglycemia Hypercholesterolemia Persistent Postoperative Pain Hip Replacement Knee Replacement Primary hip and knee replacement for osteoarthritis Enrolled previously into study NCT01021826  Arthritis other than osteoarthritis (based on study NCT01021826) Medication affecting glucose metabolism (excl. antidiabetic agents) (based on study NTC01021826) Died before follow-up phase Did not undergo the planned hip or knee replacement


eligible ages (years): 18.0-999.0,  All  Deep Vein Thrombosis Pulmonary Embolus ≥ 18 years Investigator judges caval filtration clinically indicated for prevention of pulmonary embolism in patient with venous thromboembolic disease or at high risk for venous thromboembolic disease. Patient must meet at least one of the following Anticoagulant therapy is contraindicated, has failed, cannot be achieved or maintained, must be interrupted, resulted in complication, or places the patient at high risk of complication and the patient has Pulmonary embolus Iliocaval deep vein thrombosis (DVT) Severe trauma with high risk of venous thromboembolism including closed head injury, spinal cord injury, or multiple long bone or pelvic fractures Surgery planned with high risk of venous thromboembolism including procedures such as bariatric, orthopedic, or pelvic surgery Past history of thromboembolic disease undergoing surgery Therapeutic anticoagulation can be achieved, but the patient has Venous thromboembolism such as pulmonary embolism or DVT with limited cardiopulmonary reserve  Condition that inhibits radiographic visualization of the IVC Known inadequate venous anatomy to allow insertion or retrieval of the filter from the IVC including occlusion of the SVC or jugular veins Known IVC transverse diameter at target implant site > 28 mm Known obstructing abdominal mass or anatomy that is not suitable for infra-renal placement of IVC filter Known duplication of IVC or left-sided IVC Severe kyphosis or scoliosis Known IVC thrombosis extending to renal veins, or renal or gonadal vein thrombosis Risk for septic pulmonary embolism Confirmed bacteremia Estimated Glomerular Filtration Rate (eGFR) < 30 ml/min, or dialysis dependent


eligible ages (years): 18.0-999.0,  All  Venous Thromboembolism Subjects must provide informed consent Men or women aged 18 years or more Ongoing cancer disease recent diagnosis of veinous thromboembolism treatment with Low Molecular Weight Heparin before entry into the study  Contraindication to the use of Low Molecular Weight Heparin


eligible ages (years): 16.0-999.0,  All  Cancer Thrombosis Venous Thromboembolism Deep Vein Thrombosis Pulmonary Embolus Receiving LMWH for treatment of CAT for five months Locally advanced or metastatic cancer Able to self-administer LMWH, or have LMWH administered by a carer Able to give informed consent Age ≥16 years  Receiving drug other than LMWH for CAT Contraindication to anticoagulation Fitted with a prosthetic heart valve Pregnant and/or lactating females


eligible ages (years): 18.0-99.0,  All  Breast Cancer signed an Institutional Review Board (IRB)-approved informed consent document for protocol age >= 18 years histologically confirmed left-sided breast cancer scheduled to undergo curative intent radiation treatment post lumpectomy or mastectomy stage 0-III left-sided breast cancer (including DCIS) SPECT score of 0 at baseline radiation oncologist agrees target volume coverage will not be compromised via use of the DIBH technique along with conformal field shaping  active cardiac disease, defined as a history of angina, arrhythmias, myocardial infarction, congestive heart failure, or any other cardiac condition, which in the opinion of the treating physician would make this protocol unreasonably hazardous for the patient symptomatic pulmonary disease currently requiring regular medication including but not restricted to bronchodilators concurrent chemotherapy prior receipt of mediastinal radiation therapy pregnant or lactating women inability to understand and follow breathing instructions for the DIBH procedure


eligible ages (years): 18.0-999.0,  All  Atrial Fibrillation Deep Vein Thrombosis Pulmonary Embolism age 18 years or above after study start index date on or after study start signed, informed consent patients treated for DVT or PE patients with non-valvular AF (with one or more risk factors) treated for prevention of stroke and systemic embolism  any use of univalent direct thrombin inhibitor or direct factor Xa inhibitors use of anticoagulant therapy or other vitamin K antagonists recorded within one year prior to index date


eligible ages (years): 18.0-999.0,  All  Pulmonary Embolism years of age or greater Agrees and able to participate in the study Room air SpO2 (oxygen saturation) less than 92% and newly-diagnosed PE (or controls with no PE) based on CT angiogram result  Clinical concern for instability Systolic blood pressure less than 100 mm Hg Heart rate ≥140 beats per minute Oxygen saturation less than 85% with more than 4 L supplemental oxygen Unable to participate/comply with instructions for using the incentive spirometer Patients from the Federal Medical Center in Rochester, Minnesota Patients who do not speak English (due to the need for expediency) Patients will be under the care of the Emergency Department team who have the skills and resources to monitor and treat patients if they were to become unstable


eligible ages (years): 18.0-999.0,  All  Multiple Pulmonary Emboli Patients referred for CT pulmonary angiogram to pulmonary embolus  Class 3 or 4 Congestive Heart Failure Supraventricular tachycardia History of contrast allergy Unable to give informed consent Patients with serum creatinine >1.28 mg/dl without referring physician approval


eligible ages (years): 50.0-999.0,  All  Diabetes Diabetes Mellitus, Type 2 Type 2 diabetes Age above or equal to 50 years with predefined previous cardiovascular disease(s) or renal disease or age above or equal to 60 years with predefined cardiovascular risk factors HbA1c (glycosylated haemoglobin) above or equal to 7.0% or HbA1c below 7.0% and current insulin treatment corresponding to above or equal to 20 U of basal insulin per day One or more oral or injectable antidiabetic agent(s)  An acute coronary or cerebrovascular event in the previous 60 days Planned coronary, carotid or peripheral artery revascularisation Chronic heart failure NYHA (New York Heart Association) class IV Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell skin carcinoma)


eligible ages (years): 18.0-80.0,  All  Acute Pancreatitis Complication of Ventilation Therapy Diagnosis of pancreatitis:typical pain, increase in serum lipase or amylase, onset of abdominal pain within 72h before admission The diagnosis of Severe Acute Pancreatitis is according to Atlanta revisited in 2012 the diagnosis of ARDS meets the of Berlin definition  chronic respiratory disease as chronic obstructive pulmonary disease (COPD), asthma organic cardiopathy pregnancy


eligible ages (years): 18.0-75.0,  All  Cardiac Disease Patients aged 18-75 years inclusive and American Society of Anesthesiologists physical status 2-4 Undergoing minimally invasive cardiac surgery Subjects must be physically and mentally able to participate in the study and complete all study assessments Subjects must be able to give fully informed consent to participate in this study after demonstrating a good understanding of the risks and benefits of the proposed components of thoracotomy and chest tube sites infiltration  History of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics Any subject whose anatomy, or surgical procedure, in the opinion of the Investigator, might preclude the potential successful performance of a thoracotomy and chest tube sites infiltration Any subject who in the opinion of the Investigator, might be harmed or be a poor candidate for participation in the study Any subject, who in the opinion of the Investigator, is on chronic pain medicine, including large doses of nonsteroidal antiinflammatory drugs Subjects who have received any investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during their participation in this study


eligible ages (years): 18.0-75.0,  All  Chest Pain patients undergoing removal of a chest tube after lung surgery patients able to indicate the pain score  pregnancy, lactation  insulin-dependent diabetes with dysautonomia central or peripheral neurological disease, agitation inability to understand the protocol inability to use the Pain Monitor: skin abnormalities at the site of measurement, pacemaker or implantable defibrillator, condition affecting the sympathetic nervous system, tremor of the extremities contra-indication to oral morphine  respiratory failure, severe hepatic insufficiency, intracranial hypertension, epilepsy associations recent administration of neostigmine or of atropine


eligible ages (years): 0.25-16.0,  All  Dengue Disease Progression Age >3 months and <16 years Clinical suspicion of dengue hemorrhagic fever. (Revised WHO Classification System) Not a prisoner or ward of the state Parents able and willing to give consent. Children older then 7 able and willing to give assent  Allergic to Ultrasound gel Prisoners or wards of the state Unstable patients Known pleural effusion, ascites, or gallbladder wall thickening


eligible ages (years): 18.0-999.0,  All  Hip Pain Patients undergoing surgery for painful external snapping hip years or older  Inability to comply with the protocol (e.g. due to dementia)


eligible ages (years): 15.0-999.0,  All  Postoperative Pain Elective minimally invasive surgical correction of funnel chest (pectus excavatum age ≥15 years  Previous thoracic surgical interventions Presence of diseases affecting the central and/or peripheral nervous system Presence of chronic pain conditions Inability to speak and/or understand Danish Inability to understand and participate in the experimental pain session Presence of psychiatric disorders History of frostbite in the non-dominant upper limb Presence of sores or cuts on non-dominant upper limb Presence of cardiovascular disease History of fainting and/or seizures


eligible ages (years): 21.0-85.0,  All  Ischemic Stroke Patients 21-85 years old, male or female Suspected acute ischemic stroke based on clinical and radiographic evidence as determined and documented by the Stroke Neurology team at University of Kentucky Patients must meet for intra-arterial thrombolysis as determined and documented by Interventional Neuroradiology attending physician (JF or AA) Patients must have an acute thromboembolus within an intracranial artery (internal carotid, anterior cerebral, middle cerebral, posterior cerebral, basilar, vertebral) which undergoes pharmacologic (tissue plasminogen activator tPA) and/or mechanical (eg. Merci or Penumbra clot retrieval) thrombolysis Patients with impaired capacity may be included, as the pathology to be studied (stroke) may impair their capacity (please see attached required documentation regarding impaired capacity) Patients must have a TICI 2A or better revascularization via intra-arterial thrombolysis For reference, the TICI Scale is defined below = No Perfusion = Perfusion past the initial obstruction but limited distal branch filling with little or slow distal perfusion  Pregnant women (would not qualify for intra-arterial thrombolysis as standard of care) Patients who undergo intra-arterial thrombolysis for acute stroke, in whom only TICI 0 or 1 revascularization is obtained Patients with occlusion of the cervical common or internal carotid artery will be excluded from the study


eligible ages (years): 18.0-999.0,  All  Venous Thromboembolism Patients aged 18 years or older with an objectively verified diagnosis of DVT and/or PE and treated according to routine clinical practice with Rivaroxaban  Patients in whom follow-up is unlikely or impossible Patients unable to give consent Patients who receive heparin therapy for more than 48 hours Patients who receive more than one dose of warfarin Patients with an indication for anticoagulation other than DVT and/or PE All contraindications listed in the local product information (SmPC) will form part of the


eligible ages (years): 18.0-999.0,  All  Venous Thrombosis Pulmonary Embolism Lung Neoplasms Patient At least 18 years of age Either gender Diagnosed with resectable lung cancer or metastatic lung disease eligible to complete metastasectomy Undergoing one of the following surgeries: Segmentectomy, wedge resection, lobectomy, bilobectomy or pneumonectomy Competent to understand and sign consent documents Patient  Known allergic or anaphylactic reaction to contrast dye, heparin or low molecular weight heparin (LMWH) Under current anticoagulation for venous thromboembolism or other medical conditions Known renal impairment, defined as creatinine clearance value of less than 55ml/min/m2 as calculated by the Cockroft-Gault method History of, or ongoing liver disease, manifested as ascites or previous peritoneal tapping for ascites Pregnant or planning to become pregnant Diagnosed or treated for VTE in the past 3 months prior to surgery Present or previous increase risk of haemorrhage History of previous HIT (heparin induced thrombocytopenia) Platelet count must be below 75,000 Previously inserted Inferior Vena Cava Filter (IVC) filter


eligible ages (years): 0.0-999.0,  All  Venous Thromboembolism all patients undergone primary total knee arthroplasty  renal insufficiency, contrast allergy, simultaneous bilateral TKA, hemorrhagic disorder, sever liver disease


eligible ages (years): 18.0-999.0,  All  Pain, Postoperative Anesthesia, Conduction Arthroplasty, Replacement, Hip Primary total hip replacement  general anaesthesia Allergy to local anesthetics of the amide type Revision surgery Bilateral surgery Chronic pain patient Women in the fertile age


eligible ages (years): 18.0-999.0,  All  Venous Thromboembolism Lung Neoplasms Pulmonary Embolism Patients must be at least 18 years of age Patient may be of either gender Patients must be diagnosed with resectable lung cancer or metastatic lung disease eligible to complete metastasectomy Patients must be undergoing one of the following surgeries: Segmentectomy, wedge resection, lobectomy, bilobectomy or pneumonectomy Patients must be competent to understand consent documents  All patients with known allergic or anaphylactic reaction to contrast dye, heparin or low molecular weight heparin (LMWH) Patients must not be under current anticoagulation for venous thromboembolism or other medical conditions Patients must not have known renal impairment (defined as estimated glomerular filtration rate of less than 30ml/min/m2 as calculated by the Cockcroft-Gault method) either pre-operatively or as identified based on blood work obtained prior to the scheduled 30-day post-operative scan Patients must not have known hepatic failure, with international normalized ratio (INR) of >1.5 Patients with history of, or ongoing liver disease, manifested as ascites or previous peritoneal tapping for ascites Patients must not be pregnant or planning to become pregnant Patients must not have been diagnosed or treated for VTE in the past 3 months prior to surgery Patients must not have a known, objectively confirmed bleeding disorder Patients must not have a present or previous increase risk of haemorrhage Patients must not have a history of previous heparin induced thrombocytopenia


eligible ages (years): 18.0-999.0,  All  Pulmonary Embolism Pulmonary Embolism, diagnosed by CTA or high probability VQ Scan Total Pulmonary Embolism Severity Index (PESI) score <86  Massive Pulmonary Embolism: Hypotension with signs of right heart strain on CTA or Echocardiogram Sustained Systolic Blood Pressure (SBP) <95 mmHg during Emergency Department or observation stay Age <18 Pregnant Renal insufficiency (Creatinine Clearance <30) Hepatic Dysfunction (AST/ALT/ALP > 3 times upper limit of normal) Unreliable social situation or inability to follow up Contraindication to enoxaparin, warfarin and rivaroxaban Atrial or ventricular dysrhythmia(s)


eligible ages (years): 18.0-999.0,  All  Pulmonary Embolism Concern for PE by attending physician and CTPA ordered  If patient is under the age of 18, a prisoner, or a ward of the state CTPA ordered but not performed


eligible ages (years): 18.0-999.0,  All  Emergency Patients Acute onset of, or worsening of dyspnea Or chest pain Low clinical pretest probability of PE, empiricially estimated by the gestalt  Other obvious cause than PE for dyspnea or chest pain Acute severe presentation Contra-indication to CTPA Concurrent anticoagulation treatment Current diagnosed thrombo-embolic event Inability to follow up Prisoners Pregnancy No social security Participation in another intervention trial


eligible ages (years): 18.0-65.0,  All  Pleural and Lung Ultrasound Twenty healthy male volunteers aged between 18 and 65 years-old with no history of respiratory or cardiovascular pathologies will be enrolled  Females and all subjects with history of respiratory or cardiovascular diseases will be excluded


eligible ages (years): 18.0-999.0,  All  Venous Thromboembolism Deep Venous Thrombosis Pulmonary Embolism All patients on the four trial floors who miss at least one dose of VTE prophylaxis will be included in the study


eligible ages (years): 18.0-85.0,  All  Postoperative Pain Patients undergoing unilateral THR and TKR who are between the ages of 18 and 85 regardless of the anesthesia and postoperative analgesia type Patients participating in other studies may participate in this study as well Patients with Motor Activity Assessment Scale (MAAS) Score of 3 and 4  Age <18, >85 History of chronic pain as defined by use of long acting opioid medication > 6 months duration MAAS Score of <3 and >4 Anticholinergic agent use Patients with the following conditions Autonomic neuropathy Pacemaker/AICD Burn patients or patients with severe dermatologic conditions (as defined by skin conditions causing further pain to patients that actively has to be treated) Allergy to adhesive tape Communication barriers


eligible ages (years): 18.0-999.0,  All  Anticoagulation For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Patients aged 18 or older over the study period Patients with a diagnosis for NVAF or VTE anytime in their medical records Patients having at least one year of enrolment in the database prior to the index date Patients newly initiated with VKA during the study period (index date)  Patients with a diagnosis for both NVAF and VTE anytime in their medical records


eligible ages (years): 14.0-40.0,  All  Groin Pain Diagnosis of athletic groin pain Professional athlete in full time training with groin pain diagnosis  Post infective osteitis Bone tumour Acute injury


eligible ages (years): 18.0-999.0,  All  Orthopaedic Decision Making Patients 18 year old or older daily smoker patients within 1 week post orthopaedic operation patient that have never received an orthopaedic related smoking cessation discussion  Younger than 18 patients unable to provide consent patients that suffer from auditory/visual/mental disability requiring another individual as a decision-maker patients in severe acute pain


eligible ages (years): 18.0-999.0,  All  Stroke Ischemic Stroke Eligible patients will be Adults (≥18years) with the final diagnosis of an acute ischemic stroke CT-Angiogram proven, large artery occlusion (LAO) in the internal carotid artery (ICA), middle cerebral artery (MCA -M1 or M2 site) locations NIH Stroke Scale ≥6 (NIHSS) OR proven LAO on imaging (must be from designated LAO listed on #2) LSN (last seen normal) to groin puncture (≤ 8 hours) in thrombectomy arm; LSN to presentation to endovascular capable center (≤ 8 hours) in medical arm Baseline modified Rankin Scale score of 0-3 Signed Informed Consent obtained Subject willing to comply with the protocol follow-up requirements Anticipated life expectancy of at least 3 months IV-tPA eligible patients must meet AHA guidelines  Patients are excluded if Inability to undergo CT-Angiography and/or CT-Perfusion imaging (e.g., renal insufficiency, iodine/contrast allergy) Co-morbid psychiatric or medical illnesses that would confound the neurological assessments


eligible ages (years): 50.0-80.0,  All  Osteoarthritis, Knee End-stage arthritis of the knee Failure of medical treatment or rehabilitation Hemoglobin > 10g/dl No use of non-steroid anti-inflammatory agent one week before operation  Preoperative Hemoglobin ≦10 g/dl History of infection or intraarticular fracture of the affective knee Renal function deficiency (GFR < 55 ml/min/1.73m2)which is relative contraindicated for venography Elevated liver enzyme, history of liver cirrhosis, impaired liver function and coagulopathy (including long-term use anticoagulant) History of deep vein thrombosis, ischemic heart disease or stroke


eligible ages (years): 18.0-999.0,  All  Missed Pulmonary Embolism at the Emergency Department patients 18 years of age or older presented to the ED between January 2011 and March 2014 who received an ECG or any form of thoracic imaging  patients below 18 years of age, as well as patients referred to the ED with suspected PE by departments within UHBS, other hospitals, or other healthcare providers


eligible ages (years): 16.0-999.0,  All  Pregnancy Suspected Deep Vein Thrombosis Compression Ultrasound D-dimer Unselected pregnant women (preciously documented positive beta hCG on urine or serum pregnancy tests) with Suspected acute symptomatic deep vein thrombosis Defined as new leg swelling or edema with onset in the last month or new leg pain (buttock, groin, thigh or calf) with onset in the last month  Prior major VTE (proximal DVT or segmental or greater PE) Below the age of legal consent in jurisdiction of residence (18 years old for Quebec and 16 years old for rest of Canada) Unable or unwilling to provide informed consent Concomitant symptoms of suspected pulmonary embolism (chest pain or shortness of breath or syncope/pre-syncope or unexplained tachycardia) Need or plan for ongoing anticoagulant therapy (>2 weeks), at any dosage (i.e. prophylaxis or treatment dosage), throughout the ante-partum period Need for therapeutic anticoagulant therapy in the post-partum period (i.e. patients that are/will be treated for superficial phlebitis, mechanical valves, atrial fibrillation or other indications)


eligible ages (years): 75.0-999.0,  All  Acute Dyspnea Admission to the Emergency Department Age ≥ 75 years AND of acute dyspnoea Breathe rate ≥ 25 cycles/minute or PaO2 ≤ 70 mmHg or SpO2 ≤ 92% in room air or PacO2 ≥ 45 mmHg and pH ≤ 7.35 AND Electrocardiogram in sinus rhythm at admission


eligible ages (years): 35.0-90.0,  All  Chronic Obstructive Pulmonary Disease A clinical diagnosis of COPD Aged between 35 and 90 years Able to fluently read and speak English Willing and able to sign informed consent Be able to comply with the procedures outlined for the study  Cardiac disease (including arrhythmias) A medicinal requirement for rate limiting calcium antagonists or beta blockers Cerebrovascular disease Peripheral vascular disease Requirement for supplemental oxygen therapy CO2 (carbon dioxide) retention Malignancy Orthopaedic or neurological conditions effecting the ability to exercise Clinically apparent heart failure Renal, hepatic or inflammatory disease


eligible ages (years): 19.0-999.0,  All  Venous Thromboembolism Adult (≥19 years of age) patients who are initiating treatment with Eliquis for the treatment of VTE or prevention of recurrent VTE for the first time in accordance with the Korean package insert will be enrolled in the study  Patients with prior treatment with Eliquis before enrollment in this study Patients receiving Eliquis treatment for an indication not approved indication in Korea Patients meeting any of the following will not be included in the study i) Hypersensitivity to the active substance or to any of the excipients ii) Clinically significant active bleeding iii) Hepatic disease associated with coagulopathy and clinically relevant bleeding risk iv) Patients with increased bleeding risk due to such as following diseases Recent gastrointestinal ulceration history Recent intracranial or intracerebral haemorrhage history Intraspinal or intracerebral vascular abnormalities


eligible ages (years): 21.0-85.0,  All  Peripheral Arterial Disease Patients with peripheral arterial disease (PAD) Capable of giving informed consent Men and women age 21 years Diagnosed with PAD (i.e., ankle-brachial index below 0.9) Fontaine stage II or less no pain while resting Satisfactory history and physical exam  Children Pregnant or nursing women Patients taking nitroglycerine or nitrate preparations Patients taking phosphodiesterase inhibitors such as sildenafil or tadalafil Patients taking proton pump inhibitors Ejection fraction < 40% Uncontrolled hypertension Uncontrolled diabetes Myocardial infarction within past 6 months or unstable angina Severe lung disease (i.e., on supplemental oxygen or frequently use rescue inhalers)


eligible ages (years): 0.0-999.0,  All  Venous Thromboembolism Patients who start rivaroxaban for VTE （pulmonary embolism, deep vein thrombosis) anticoagulation therapy  Patients who are contraindicated based on the product label and have already received Xarelto treatment


eligible ages (years): 18.0-999.0,  All  Pulmonary Embolism Age ≥18 years Objectively confirmed diagnosis of acute PE by multidetector CT angiography, ventilation/perfusion lung scan, or selective invasive pulmonary angiography, according to established diagnostic with or without symptomatic deep vein thrombosis Absence of hemodynamic collapse, or decompensation, at presentation; Hemodynamic collapse or decompensation Intermediate-risk category of PE severity indicated by a positive (score ≥1) simplified pulmonary embolism severity index (sPESI), in combination with the presence of at least one of the following at presentation At least one sign of RV pressure overload/dysfunction on CT angiography or echocardiography Signs of myocardial injury as indicated by elevated troponin levels Signs of (RV) failure as indicated by NT-proBNP levels >600 pg/ml at baseline Ability of the subject to understand the character and individual consequences of the clinical trial; signed and dated informed consent of the subject available before the start of any specific trial procedures  Pregnancy (a negative serum or urine pregnancy test should be available for women of child-bearing potential before study inclusion) or lactation Women of childbearing potential who do not practice a medically accepted highly effective contraception during the trial and one month beyond History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product Participation in another clinical trial during the present clinical trial or within the last three months Medical or psychological condition that would not permit completion of the trial or signing of informed consent Use of a fibrinolytic agent, surgical thrombectomy, interventional (catheter-directed) thrombus aspiration or lysis, or use of a cava filter to treat the index episode of PE Treatment with any therapeutically dosed anticoagulant for more than 48 hours prior to enrolment Need for long-term treatment with a low molecular weight heparin, vitamin K antagonists or NOAC, for an indication other than the index PE episode, or for antiplatelet agents except acetylsalicylic acid at a dosage ≤100 mg/day Active bleeding or known significant bleeding risk (e.g., gastrointestinal ulcer, malignant neoplasms, injuries or recent surgeries of the brain, spinal cord or eyes, recent intracranial bleedings, known or suspected esophagus varices, aneurysms or intraspinal or intracranial vascular abnormalities) Artificial heart valves requiring treatment with an anticoagulant


eligible ages (years): 18.0-999.0,  All  Pulmonary Embolism Consecutive out patients with suspected PE in whom PE has been considered ruled out by negative D-dimers using an age-adjusted cut-off  Life expectancy less than 3 months Geographic inaccessibility for follow-up Therapeutic anticoagulation for any indication Pregnancy Age less than 18


eligible ages (years): 0.0-999.0,  All  Anterior Cruciate Ligament Reconstruction Patients undergoing scheduled anterior cruciate ligament (ACL) surgery at the Emory Orthopaedic and Spine Center Patients willing and able to provide written informed consent Parents willing and able to provide written informed consent for minors  Patients who are pregnant or lactating Patients with liver dysfunction or renal failure Patients with a known allergy to ropivacaine Patients with a local infection Patients who take chronic pain medications Patients with an opioid tolerance Patients with known coagulopathy or bleeding risk Patients who are getting neuraxial anesthesia for surgery


A 47 year old male who fell on his outstretched left arm presents with pain and bruising on the inside and outside of the elbow, swelling, and inability to bend the arm. On the x-ray, the ulna has dislocated posteriorly from the trochlea of the humerus. The radius has dislocated from the capitulum of the humerus.

eligible ages (years): 6.0-16.0,  All  Narcolepsy Inclusions written informed consent/assent is obtained meet minimal established by the International Classification of Sleep Disorders (ICSD) manual of the American Academy of Sleep Medicine (AASM) for narcolepsy (or presumed narcolepsy) or OSAHS OR have a previous diagnosis of narcolepsy or OSAHS before the screening visit have a complaint of ES are in good health as determined by a medical and psychiatric history, physical examination, ECG, and clinical laboratory tests have blood pressure values greater than those for the 5th percentile and less than the 95th percentile on the National High Blood Pressure Education Program guidelines for blood pressure levels for boys and girls ages 6 to 16 years girls who are postmenarchal or sexually active, have a negative urine pregnancy test at screening, must be using a medically acceptable method of birth control, and must agree to continue use of this method for the duration of the study (and for 2 cycles after participation in the study); acceptable methods of birth control barrier method with spermicide; steroidal contraceptives (oral, transdermal, implanted, or injected) in conjunction with a barrier method; intrauterine device (IUD); or abstinence able to swallow a tablet similar in size and shape to the study drug tablet negative urine drug screen (UDS) for any illicit drug, alcohol (ethanol), stimulants at screening; if positive for stimulants (prescribed for excessive sleepiness) at screening, UDS to be repeated after a washout period and before baseline have a parent or legal representative who is willing to participate in the study  have self-induced sleep deprivation/poor sleep hygiene have a past or present seizure disorder (except history of single febrile seizure), a history of psychosis, or of clinically significant head trauma (eg, brain damage) or past neurosurgery have a history of suicide attempt, or are at suicidal risk a clinically significant drug sensitivity to stimulants such as amfetamine, dexamfetamine, or methylphenidate; and/or modafinil or any of its components use of any monoamine oxidase (MAO) inhibitors or selective serotonin reuptake inhibitors (SSRIs) within 2 weeks of the baseline visit (NOTE: SSRIs will be allowed for cataplexy if the patient has been on a stable dose for at least 1 month.) received any investigational drug (except modafinil) within 4 weeks of the baseline visit any disorder that could interfere with drug absorption, distribution, metabolism, or excretion (including previous gastrointestinal surgery) active, clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematologic, neoplastic, endocrine, neurologic, immunodeficiency, pulmonary, or other major clinically significant disorder/disease any clinically significant deviation from the normal range(s) in the physical examination or ECG findings, or clinical laboratory test results (ie, serum chemistry, hematology) at the screening or baseline visit absolute neutrophil count (ANC) below the lower limit of normal at screening (NOTE: If the ANC is below the lower limit of normal at the baseline visit, the medical monitor will be consulted for continued in the study.)


eligible ages (years): 14.0-999.0,  All  Shoulder Dislocation Ages 14 years or greater Diagnosis of MDI or MDL-AII. Diagnosis will require two or more of the following Symptomatic translation (pain or discomfort) in one or more directions: anterior, inferior and/or posterior Ability to elicit unwanted glenohumeral translations that reliably produce symptoms with one of the following tests: the anterior and posterior apprehension tests, the anterior and posterior load and shift tests, the fulcrum test, the relocation test, the Fukuda test, and/or the push-pull or stress test with the patient supine Presence of a positive sulcus sign of 1 centimetre or greater gap that reproduces the patient's clinical symptoms of instability and should be both palpable and visible Symptoms of instability: subluxation or dislocation Written informed consent Failed at least 6 months of non-operative treatment Confirmed capsular-ligamentous redundancy as determined by diagnostic arthroscopy examination  Neurologic disorder (ie: axillary nerve injury; syringomyelia) Cases involving third party compensation Patients with primary posterior instability A bony abnormality (Hill Sachs/bony Bankart) on standard series of x-rays consisting of a minimum of an anteroposterior view, lateral in the scapular plane and an axillary view Presence of a Bankart lesion on arthroscopic exam of the joint Presence of an unstable biceps anchor (ie: superior labral anterior and posterior [SLAP] lesion) on arthroscopic exam of the joint Presence of a full-thickness rotator cuff tear


eligible ages (years): 14.0-999.0,  All  Joint Instability Shoulder Dislocation Clinical Age 14 years or greater Diagnosis of traumatic anterior shoulder instability, made by meeting all of the following Radiographic evidence or documented physician assisted reduction of anterior shoulder dislocation following a traumatic injury Ability to elicit unwanted glenohumeral translation which reproduce symptoms with one of the following tests: anterior apprehension, relocation test, or anterior load and shift test Radiological Closed growth plate on a standardized series of x-rays consisting of a minimum of an anteroposterior view, lateral in the scapular plane and an axillary view  Clinical Diagnosis of multidirectional instability (MDI) or multidirectional laxity with anteroinferior instability (MDL-AII), made by two or more of Symptomatic (pain or discomfort) in inferior or posterior direction Ability to elicit unwanted posterior glenohumeral translation that reproduces symptoms with posterior apprehension tests, or posterior load and shift test Positive sulcus sign of 1cm or greater that reproduces patient's clinical symptoms Previous surgery on the affected shoulder other than diagnostic arthroscopy Cases involving litigation Significant tenderness of acromioclavicular/sternoclavicular joints on affected side Confirmed connective tissue disorder (ie: Ehlers-Danlos, Marfan)


eligible ages (years): 14.0-999.0,  All  Southern Tick-Associated Rash Illness Enrolled in protocol 02-I-0055 A person who is at least 14 years old Acute onset (within 14 days of visit to NIH) of an annular, erythematous, expanding erythema migrans (EM)-like rash that attains a size of at least 5 cm in diameter, when no alternative explanation for the rash can be found, and thought by the study physician to have a high likelihood to be due to STARI (due to exposure history, tick identification) History of tick bite at the rash site, or potential exposure to ticks in the southeastern and south central United States within 14 days prior to rash onset (including Maryland and Virginia) Consent to storage of biologic samples for later testing  A person who, in the judgment of the investigator, would be at increased risk from the skin biopsy procedure and unlikely to be able to mount a serological response to the agent (for example, bone marrow transplant, B cell deficiency) FROM SKIN OF STUDY A person who meets the case definition but whose EM-like rash occurs on the face, neck, scalp, or over the tibia will not be enrolled for purposes of obtaining a skin biopsy specimen. Such a person may enroll for purposes of providing a clinical history and blood samples only. This also applies to patients with a history of forming large thick scars after skin injuries or surgery, or who have a history of excessive bleeding after cuts or procedures or are taking anticoagulants, or have severe skin disease. Also, patients who have received more than 24 hours of antibiotic treatment for the rash will be excluded from the biopsy. Patient with a history of allergy to lidocaine will also be excluded from the biopsy portion of the study


eligible ages (years): 0.0-15.0,  All  Fracture Forearm Midshaft Child Treatment both-bone forearm fracture age < 16 years dislocation stable  fracture older than 1 week no informed consent refracture open fracture (Gustillo 2 and 3)


eligible ages (years): 0.0-15.0,  All  Fracture Forearm Distal Child Treatment both-bone forearm fracture distal dislocated unstable after reposition age < 16 years  fracture older than 1 week no informed consent refracture open fracture (Gustillo 2 and 3) both fractures of type torus


eligible ages (years): 15.0-18.0,  All  Forearm Injuries Children that had had Ulna or Radius X-rays Signing Informed consent  Unwillingness to sign informed consent


eligible ages (years): 0.0-999.0,  All  Degenerative Conditions of the Radial Head/Neck Post-traumatic Conditions of the Radial Head/Neck The will be the same as the indications stated in the FDA cleared (510(k) K040611) and (510(k) K051385) labeling for the device Replacement of the radial head for degenerative or post-traumatic disabilities presenting pain, crepitation, and decreased motion at the radio-humeral and/or proximal radio-ulnar joint with Joint destruction and/or subluxation visible on x-ray Resistance to conservative treatment Primary replacement after fracture of the radial head Symptomatic sequelae after radial head resection Revision following failed radial head arthroplasty The device is intended for single use with or without bone cement Modular Radial Head replacement prostheses have received FDA clearance for cemented and non-cemented application Patient selection factors to be considered 1) need to obtain pain relief and improve function, 2) ability and willingness of the patient to follow instructions, including control of weight and activity levels, 3) a good nutritional state of the patient, and 4) the patient must have reached full skeletal maturity  The will be the same as the contraindications stated in the FDA cleared labeling (510(k) K040611) and (510(k) K051385) for the device. These contraindications Absolute contraindications Infection Sepsis Osteomyelitis Relative contraindications Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions Osteoporosis Metabolic disorders which may impair bone function


eligible ages (years): 19.0-999.0,  All  Patellar Dislocation An acute primary traumatic patellar dislocation  Previous dislocation or subluxation of the patella Pre-existing ipsilateral or contralateral knee pathology Previous knee trauma or patellar fracture


eligible ages (years): 18.0-999.0,  All  Heterotopic Ossification Subjects aged 18 years or greater Operative treatment of one of the following injuries An elbow dislocation with or without associated fractures An olecranon fracture-dislocation, but not simple olecranon fractures A distal humerus fracture  An existing diagnosis of one of the following conditions Injury to the central nervous system, thorax, or abdomen precluding the immediate use of non-steroidal anti-inflammatory medications Fracture of any long bone since non-steroidal anti-inflammatory medications may increase the risk of nonunion History of gastritis, peptic ulcer disease, or upper gastrointestinal bleeding Impaired renal function (creatinine > 2.0), hypovolemia, heart failure, high blood pressure ( > 160/90), fluid retention, asthma, liver dysfunction (bilirubin > 2.0), or a coagulation disorder Allergy to non-steroidal anti-inflammatory medications Asthma, nasal polyps, urticaria, and hypotension associated with the use of NSAIDs Considerable dehydration Pregnant or breast-feeding women Concomitant use of one of the following drugs


eligible ages (years): 14.0-30.0,  All  Shoulder Dislocation to 30 years of age Willing to participate in follow-up for at least two years Acute, first-time, traumatic, isolated anterior dislocation of the shoulder  Previous instability of the affected shoulder A history of significant ligamentous laxity or demonstrated multi-directional instability of the opposite shoulder Inability or unwillingness to comply with sling immobilization, rehabilitative protocol, or required follow-up assessments Incompetent or unwilling to consent A medical condition making the patient unable to wear a sling Significant associated fracture (Exception Hill Sachs of >20% or bony Bankart lesions>10%) Neurovascular compromise of the affected limb Concomitant ipsilateral upper extremity injuries which may affect the patient's ability to participate in, or benefit from, a rehabilitative program


eligible ages (years): 50.0-85.0,  All  Osteoarthritis Diagnosis of osteoarthritis Eligible for a unilateral or bilateral primary TKA to be performed by Dr. Michael Dayton (University of Colorado Hospital) Minimum of 110 degrees of active knee flexion No greater than 10 degrees of anatomic knee varus, 15 degrees anatomic valgus, and 10 degrees flexion contracture Body mass index less ≤ 40 kg/m2  Any brain, circulation, or heart problems that limit function Severe osteoarthritis or other orthopedic conditions that limit function in the lower extremity that is not undergoing the TKA


eligible ages (years): 17.0-38.0,  All  Shoulder Instability Surgical documentation of Pan Labral Lesion of shoulder Pre-operative documentation of outcomes scores  lacking a Pan labral lesion other confounding pathology such as nerve deficit, chondral damage, rotator cuff tear


eligible ages (years): 0.0-999.0,  All  Rotator Cuff Tear Medium to large sized cuff tear (2-4 cm) Yes subscapular partial fraying or longitudinal split side to side Yes acromioplasty Yes AC arthritis with mumford procedure Yes biceps tenotomy or tenodesis  No arthritic changes of glenohumeral joint No combined infection No mini-open procedures No complete subscapularis tear No incomplete repair No small tears or side to side repairs without anchors No pregnancy


eligible ages (years): 18.0-999.0,  All  Distal Radius Fracture Distal radius fracture treated with surgical management and wrist flexion contracture upon follow up  Carpal Fractures (Scaphoid, Lunate, Hamate, and Trapezium) Radial nerve entrapment Arthrodesis Traumatic dislocation of the distal ulna


eligible ages (years): 0.0-18.0,  All  FEVER The estimates and the measurements will be carried out on children who are referred to an emergency unit and who are hospitalized in the pediatric department- both boys and girls of all ages. A patient might be measured several times


eligible ages (years): 18.0-70.0,  All  Distal Radius Fracture All patients admitted to Ahus and Lillestrom legevakt with a distal radius fracture are to be classified according to the system of the Orthopaedic Trauma Association (AO/OTA) All patients between the age of 18 and 70 diagnosed with a C2 or C3-type fracture, or a dislocated C1-fracture, are eligible for inclusion  Gustillo-Anderson type III open fractures Previous distal radius/ulna-fracture and/or disabling hand injury of the same extremity Dementia Congenital anomaly Bilateral radius fracture Pathological fracture other than osteoporotic fracture Congenital bone disease (for example osteogenesis imperfecta) Age below 18 and above 70 Disabling nury to other parts og the movement apparatus at the same time as the current injury


eligible ages (years): 18.0-60.0,  All  Acromio-clavicular Joint Dislocation (Type III) men or women ≥ 18 years-old AC joint dislocation type III with Zanca X-ray view demonstrating CC distance of 200% trauma-surgery delay of less than 14 days consent form signed  AC joint dislocation type I, II, IV, V or VI associated neuro-vascular damage men or women > 60 years-old open dislocation local skin damage dislocation in a polytrauma patient floating shoulder fracture of the ipsilateral or controlateral arm or shoulder girdle fracture of the coracoid process of the scapula history of previous surgery to the shoulder


eligible ages (years): 18.0-99.0,  All  Lyme Disease Borrelia Burgdorferi for the diagnosis of Lyme disease can be found at The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America (4) Patients With EM (N=35), Post Treatment Age 18 or older EM diagnosed by the study physician or, with a diagnosis of EM that is thought to be highly likely by the study physician Treatment with at least 1 course of antibiotics that fulfills the Infectious Diseases Society of America guidelines for the recommended therapy for Lyme disease. There must be at least 1 month and up to 4 months between the end of the therapy and the study procedures High C6 Antibody Titer (N=35) Age 18 or older Diagnosed with confirmed or probable early or late Lyme disease as per Centers for Disease Control and Prevention (CDC) case definition (http://www.cdc.gov/ncphi/disss.nndss/caseded/lyme disease 2008.htm), have received recommended antibiotic therapy and have a high C6 ELISA titer (index above 3) at least 6 months after therapy Post Lyme disease syndrome (N=20) Age 18 or older  History of allergy to surgical tape or Nitex nylon mesh History of severe reactions to tick bites (granuloma or systemic reactions) Inability to maintain the dressing for any reason Currently receiving any antibiotic or having received antibiotics in the last month (3 months for patients with post Lyme disease syndrome and high C6 titer) (except patients with EM on treatment) Pregnancy or lactation Unwillingness to use an effective method of birth control for 3 months after tick placement (women of child-bearing potential only) Not able to understand all of the requirements of the study or unable to give informed consent and/or comply with all aspects of the evaluation Investigational therapy during the time of the study and/or in the month prior to signing the informed consent Active severe skin disease, uncontrolled diabetes, cancer other than non-melanoma skin cancers, autoimmune disease requiring immunosuppressive therapy, or history of HIV, chronic viral hepatitis, or syphilis Oral steroids in the previous 2 weeks (nasal steroids and replacement doses of steroids are not exclusions)


eligible ages (years): 18.0-999.0,  All  Traumatic Knee Dislocation Ambulation without aids in pre-morbid condition Multi-ligament knee injury with or without associated peri-articular fracture Operative management within three weeks of the injury  Poly-trauma with life-threatening injuries preventing rehabilitation Patients unable to comply with intensive rehabilitation Patients unable or unlikely to maintain follow-up


eligible ages (years): 0.5-1.0,  All  Influenza Boys or girls and aged >= 6 months old to <= 12 months old on the day of first vaccination Subject's parent(s) or legal guardian(s) must be willing to comply with planned study procedures and be available for all study visits Subject must be in good physical health on the basis of medical history, physical examination Subject's parent(s) or legal guardian(s) must read and signed the study-specific informed consent prior to initiation of any study procedure  Subjects had received influenza vaccine History of hypersensitivity to eggs or egg protein or similar pharmacological effects to study medication Personal or family history of Guillain Barre' Syndrome An acute febrile illness within 1 week prior to vaccination Current upper respiratory illness (URI), including the common cold or nasal congestion within 72 hours Subjects with influenza-like illness as defined by the presence of fever (temperature >= 38'C) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough;Treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent Immunodeficiency, immunosuppressive or significant chronic illness not suitable for inactivated influenza vaccination History of wheezing or bronchodilator use within 3 months prior to study vaccine Receipt of live virus vaccine within 1 month prior to study vaccine or expected receipt vaccination before the last blood sampling for immunogenicity evaluation


eligible ages (years): 8.0-35.0,  All  Adolescent Developement Brain Developmental Biology Sample 1 Child volunteers will qualify for if they meet the following Good general health and normal IQ Age 8 years Body Mass Index (kg/m2) between the 15th and 85th percentiles for age and sex according to the US Centers for Disease Control and Prevention 2000 growth charts (103) A normal tempo of growth as determined by skeletal age within +/ 64 standard deviations of chronologic age according to the Greulich and Pyle radiographic atlas (102) (i.e., no evidence for precocious puberty or abnormal delay of maturation); Research for determining bone age will be performed by the collaborating pediatric endocrinologist. This criterion is required only for the initial entry into this study and is not one of the for subsequent visits No history of significant neurologic or cognitive disorders. Examples neonatal anoxic encephalopathy, seizure disorders, autism, and most learning disorders including attention deficit hyperactivity disorder Able to provide assent. Parents will provide consent  Child volunteers will be excluded for the following reasons Presence of any medical condition that increases risk for MRI (e.g., pacemaker, metallic foreign body in eye or other body part, dental braces) Presence or history of medical conditions known to affect cerebral anatomy Children who are not pre-pubertal as indicated by the presence of Tanner stage 2 development (i.e., areolar development in girls and testicular volume > 3 cc in boys) Individuals who have, or whose parent or guardians have, current substance abuse or a psychiatric disorder or any other condition which, in the opinion of the investigators, would impede the ability to give informed consent or possibly hinder completion of the study; presence of any psychiatric disorder in the subject, sibling, or other first-degree relative Subjects who regularly use prescription medications (the use of over-the-counter medications will be reviewed on a case-by-case basis.) For females who have reached menarche: Pregnancy, lactation, or inability or unwillingness to undergo pregnancy testing (a urine pregnancy test will be performed prior to all MRI and X-ray procedures for girls who have had the onset of menses) Current or past use of psychiatric medication I.Q. < 70 Sample 2


eligible ages (years): 0.5-6.0,  All  Nursemaid Elbow Pulled Elbow Pulled elbow suspected in any child presenting one of the following History of an adult or bigger person that had pulled the child's elbow non-intentionally Presence of intense pain at the arrival at the emergency department and unwilling to move the arm  Any suspect of injury that could be intentional (child abuse) Any suspicion child of suffering a possible fracture (the mechanism of the injury was not from pulling the child's arm, the arm presents obvious deformity, ecchymoses, edema, etc.) The mechanism was from multiple trauma Any chronic disease affecting the adequate bone mineralization (vitamin D deficiency, osteogenesis, etc.)


eligible ages (years): 8.0-12.0,  All  Metabolic Syndrome X Pupils in 3rd and 4th grades Primary Schools in the Zealand Region and Capital Region of Denmark Schools with an available school kitchen, that can be approved by the food authorities Schools where at least 60 % of the pupils in three or more classes signs up to participate in the Study  The children should not participate in a scientific study or have participated in a scientific study within the last 4 weeks. This, however depends on the character of the other study The children must not suffer from serious food allergies or food intolerance The children must not suffer from diseases or conditions that makes them ill-suited for participation in the study, eg. malabsorptive conditions or serious mental disorders The schools must not offer an well-established common meal plan, that provides most of the pupils with healthy food on a daily basis


eligible ages (years): 18.0-80.0,  All  Distal Radius Fracture Wrist Contracture Distal radius fracture treated with surgical management and wrist flexion contracture upon follow up  Carpal Fractures (Scaphoid, Lunate, Hamate, and Trapezium) Radial nerve entrapment Arthrodesis Traumatic dislocation of the distal ulna


eligible ages (years): 18.0-85.0,  All  Elbow Trauma Requiring Operative Management Terrible Triad Radial head fracture surgical treatment Monteggia and Trans-olecranon Fracture Dislocations Distal Biceps Tendon Injuries Distal Humerus Fractures Coronoid Fractures Capitellar-Trochlear fractures Olecranon Fractures  Associated Traumatic Brain Injury Burn Injuries associated with elbow trauma History of Gastric Ulcers Documented allergies to any Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Severe Asthma Previous operative fixation to affected elbow Participation in other research study Inability to speak / understand English


eligible ages (years): 1.0-17.0,  All  Fracture Treatment Children age 1-17 with buckle fractures of the distal radius and/or ulna. -  Patients are excluded if there is any other injury to the upper limb or serious bodily trauma that might complicate pain scores. Children with suspected or proven metabolic bone disease, or pathologic fractures are excluded due to resultant abnormal bone healing


eligible ages (years): 4.0-18.0,  All  Cerebral Palsy Patient Undergoing Hip Surgery Quality of Life Ages 4-18 Undergoing surgical treatment for hip subluxation or dislocation Diagnosis of cerebral palsy or similar condition causing motor impairment Consent to participate  Diagnosis of neuromuscular disorders other than cerebral palsy younger than 4, older than 18 Reimer's migration percentage <40%


eligible ages (years): 9.0-14.0,  All  Female Puberty Female volunteers in early to mid-puberty (i.e. late Tanner 1 [estradiol level >20 pg/ml], Tanner 2, or Tanner 3) Premenarcheal  BMI-for-age > 85th percentile or < 5th percentile Pregnancy Inability to comprehend what will be done during the study or why it will done Hyperandrogenism (e.g., hirsutism, elevated free testosterone level) History of allergy to progesterone (which is extremely rare) Hemoglobin less than 12 g/dl and hematocrit less than 36% Persistently abnormal sodium, potassium, or bicarbonate (i.e. confirmed on repeat) Persistently elevated creatinine, hepatic transaminases, or alkaline phosphatase (i.e., confirmed on repeat) Total bilirubin > 1.5 times upper limit of normal (i.e. confirmed on repeat) Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure; asthma requiring intermittent systemic corticosteroids; etc.)


eligible ages (years): 0.25-15.0,  All  Sinusitis, Acute Child with ABRS with inflammation as bacterial infection who has the following symptoms/signs on the day of or the day before the first dose of the investigational product: Redness of the nasal mucosa; nasal or postnasal discharge is purulent or mucopurulent; Pathological shadow in the paranasal sinus on a radiogram (only for reference). Patient with surgical history should be excluded but patient with a pervious surgery more than 365 days before and apparently preserved maxillary sinus mucosa or patient with a previous surgery of nasal polypectomy more than 90 days before may be enrolled in the study Child with ABRS whose severity is classified as moderate or severe (total score >=4) based on the nasal cavity findings and symptoms Boy or girl aged >=3 months to <15 years Body weight >=6 kilograms (kg) to <40 kg Written informed consent has been obtained from the child's legally acceptable representative. If the child is 12 years or older, the child him/herself should have also provided written informed consent. The investigator (or sub-investigator) should attempt to obtain written informed consent from the child him/herself as far as possible even if the child is less than 12 years of age  Severe infection that requires surgical treatment (e.g., child with systemic symptoms such as fever associated with swelling face, child with almost full nasal obstruction due to a large nasal polyp) Serious complication such as acute mastoiditis, facial palsy, bacterial meningitis, and brain tumor Congenital disorder such as maxillofacial dysplasia Need of concomitant use of other antibiotics Serious underlying disease (e.g., cardiac disease, malignancy, juvenile diabetes) Concurrent infection associated with gastrointestinal symptoms (e.g., diarrhoea, vomiting) that may affect safety assessment Known hypersensitivity to any component of CVA/AMPC or penicillin or cephem antibiotic, or past history of a serious adverse reaction possibly related to any of these agents Infectious mononucleosis Current hepatic impairment, or past history of jaundice or hepatic impairment due to any component of CVA/AMPC Past or current renal impairment (e.g., serum creatinine >=1.5 × Upper Limit of Normal, creatinine clearance of less than 30 milliliter/liter [mL/L])


eligible ages (years): 50.0-999.0,  All  Osteoarthritis, Hip Age greater than 50 years Undergoing primary total hip arthroplasty at Holland Orthopaedic and Arthritic Centre  Any previous surgery about the ipsilateral hip Patients being considered for simultaneous bilateral total hip arthroplasty Patients with a neuromuscular disorder or recognized hypermobility syndrome Patients without sufficient language skills to communicate in spoken and written English


eligible ages (years): 18.0-45.0,  All  Lateral Epicondylitis Individuals who meet all of the following are eligible for enrollment into the study Adult between 18-45 years of age Pain over the lateral humeral epicondyle provoked by at least two of the following: gripping, palpation, stretching of forearm extensor muscles and resisted wrist or middle finger extension Persistent pain for at least 3 months despite conservative treatments including medication (oral nonsteroidal antiinflammatory drugs (NSAIDs) and analgesics), brace application, or physiotherapy Patients with structural tendon changes at the origin of the extensors, demonstrated during musculoskeletal ultrasound Individuals who meet any of the following are disqualified from enrollment of the study  Patients with a history of advanced cervical arthrosis in the C4-C6 segments Bilateral LE with central sensitization Symptoms compatible with posterior interosseous nerve entrapment Previous surgery, fractures, trauma or previous history of rheumatic disorders in the area of the lateral epicondyle History of corticosteroid injection at the lateral epicondyle within the last 3 months Two experienced professionals performed recruitment and examination of subjects in order to assess for criteria. All eligible patients provided written informed consent


eligible ages (years): 70.0-999.0,  All  Distal Radius Fracture Dorsally displaced, 20 degrees or from a plane perpendicular do the diaphyseal axis, fracture Low energy injury Patient 70 years old or older hours or less since injury at time of diagnosis Patient registered in the Stockholm region Patient understands spoken and written swedish  Intraarticular displacement in radiocarpal joint of more than 1 mm Ulna fractured proximal to the base of the styloid process of ulna Earlier unilateral functional impairment of hand/wrist Injury to tendon, nerve or skin besides the fracture Rheumatoid arthritis or other severe systemic joint disease Severe psychiatric disorder, ongoing drug abuse or dementia (Pfeiffer score 5 points or less) Besides the wrist fracture also other big injuries, for example fracture of hip, shoulder or ankle Medical illness that makes general anesthesia impossible